HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

NCT05621499 | Unknown

• 1 other identifier: C20221044
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• 1-year DFS rate

  To evaluate the 1-year disease free survival rate of neoadjuvant treatment with HAIC or Lenvatinib combined with Sintilimab for of high recurrence risk resectable stage IB solitary hepatocellular carcinoma

  up to 1 years

Secondary Outcomes (6)

• Incidence of microvascular invasion

  Up to 3 years

• Pathological complete response rate (pCR)

  up to 1 years

• Objective response rate

  Up to 1 years

• 2-year DFS rate

  Up to 3 years

• 2-year OS rate

  Up to 3 years

Study Arms (2)

experimental group1

EXPERIMENTAL

HAIC

Drug: HAIC

experimental group 2

EXPERIMENTAL

Lenvatinib+Sintilimab

Drug: Sintilimab; Drug: Lenvatinib

Interventions

HAIC DRUG

Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles

experimental group1

Sintilimab DRUG

200mg，iv，d1，q3w，a total of 3 cycles

Also known as: IBI308

experimental group 2

Lenvatinib DRUG

12 or 8mg/kg，po，qd，a total of 3 cycles

experimental group 2

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteer to join the study and signed the informed consent form
• Aged 18-75, male or female
• ECOG PS score 0-1
• Child Pugh liver function Grade A
• Histopathology confirmed primary hepatocellular carcinoma (HCC) and the lesion met the indications for surgical resection in the Diagnostic and Therapeutic Norms for Primary Liver Cancer (2022)
• According to the investigator's assessment, there are the following high recurrence risk factors, Stage Ⅰ b: solitary tumor, with the largest diameter \> 5cm
• At least one measurable lesion according to RECIST 1.1 (measurable lesion CT/MRI scan length diameter ≥ 10mm or lymph node lesion CT/MRI scan short diameter ≥ 15mm, and measurable lesion has not received radiotherapy, cryotherapy and other local treatments)
• Expected life ≥ 6 months
• Functions of important organs shall meet the following requirements (excluding the use of any blood component and cell growth factor within 14 days) Neutrophils ≥ 1500/mm3Platelet count ≥ 60,000/mm3Hemoglobin ≥ 5.6 mmol/L (9 g/dL); Serum creatinine (SCR) ≤ 1.5 times the upper limit of normal value (ULN) or creatinine clearance ≥ 50 ml/min (Cockcroft Gault formula); Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); The level of AST or ALT ≤ 2.5 times the upper limit of normal value (ULN); Urine protein\<2+; If urinary protein ≥ 2+, the 24-hour urine protein quantitative display must be ≤ 1g
• Normal coagulation function, no active bleeding and thrombosis disease
• International normalized ratio INR ≤ 1.5 × ULN；
• Partial thromboplastin time APTT ≤ 1.5 × ULN；
• Prothrombin time PT ≤ 1.5ULN;
• Women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the medication period and within 6 months after the end of medication; If the serum or urine pregnancy test was negative within 7 days before the study included, and the patient must be a non lactating patient, the male should agree to use contraception during the study period and within 6 months after the end of the study period
• The subjects had good compliance and cooperated with follow-up.

You may not qualify if:

• Previously received radiotherapy, chemotherapy, concurrent radiotherapy and chemotherapy or other targeted therapies
• Known hepatobiliary cell carcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar cell carcinoma; Have other active malignant tumors except HCC within 5 years or at the same time
• Patients with hypertension who cannot be well controlled after antihypertensive drug treatment (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); Previous hypertension crisis or hypertensive encephalopathy
• Patients had other malignant tumors in the past or at the same time (except cured skin basal cell carcinoma and cervical carcinoma in situ);
• Patients who had been treated with Sintilimab or other PD-1/PD-L1 inhibitors in the past could not be included; Known hypersensitivity to macromolecular protein preparations or any excipients of Sintilimab or lenvatinib
• Patients have any active autoimmune diseases or have a history of autoimmune diseases (Including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Patients with vitiligo or asthma in childhood has completely alleviated, without any intervention after adulthood can be included; Patients with asthma requiring medical intervention of bronchodilators cannot be included)
• Patients who are using immunosuppressive agents, or systemic or absorbable local hormone to achieve immunosuppressive purpose (Dose\>10mg/day prednisone or other equivalent therapeutic hormones) and continue to use them within 2 weeks before enrollment
• Ascites or pleural effusion with clinical symptoms and requiring therapeutic puncture or drainage
• There are clinical symptoms or diseases of the heart that are not well controlled, such as:
• Heart failure above NYHA level 2
• Unstable angina pectoris
• Myocardial infarction occurred within 1 year
• Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
• Patients having gastrointestinal diseases such as esophageal varices, active gastric and duodenal ulcers, ulcerative colitis, portal hypertension, or active bleeding from tumors that have not been removed, or other conditions that may cause gastrointestinal bleeding and perforation as determined by the investigator at present (within 3 months)
• Serious bleeding (\>30 ml bleeding within 3 months), hemoptysis (\>5 ml fresh blood within 4 weeks) or thromboembolism (including stroke and/or transient ischemic attack) occurred in the past or present

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

Study Sites (1)

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300060, China

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

sintilimab; lenvatinib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Central Study Contacts

Yunlong Cui

CONTACT

18622228633; ningyunlong@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 10, 2022
• First Posted: November 18, 2022
• Study Start: November 1, 2022
• Primary Completion: November 1, 2023
• Study Completion: November 1, 2025
• Last Updated: November 18, 2022

Record last verified: 2022-11

Locations

CN (1)